by Ryan Choi8/12/2021

Today, YC funds more seed stage biotech companies than any other investor. To help further the mission of our biotech and hard science startups, YC is now expanding YC’s job platform to support science-related roles.

by Reshma Khilnani, Jared Seehafer3/3/2021

A frequent question we get at YC is “when do I start thinking about the FDA Obviously, there is no single answer to such a complex question, but here are some basic rules of thumb for how to think about it.

by Reshma Khilnani, Jared Seehafer3/2/2021

One of the most common topics YC Bio founders ask us about is the US Food and Drug Administration (FDA), and the broader regulatory environment. As a starting point, we wanted to touch on some of the most important concepts bio founders should think about.

by Reshma Khilnani1/20/2021

Running a biotech company is capital intensive, and this can make it intimidating to get started. Founders sometimes face a chicken and egg problem: how do you make progress without millions of dollars in funding, and how do you raise millions of dollars in funding without having made progress?

by Jared Friedman10/28/2020

This is advice for people who have done scientific research at a university and are considering starting a company to commercialize it.

by Jared Friedman10/14/2020

Shasqi is the first YC Bio company to start first-in-human clinical trials for a drug.

by Jared Friedman3/25/2020

In order to confront the COVID-19 crisis, we need to immediately mobilize global scientific and technical talent. There are already a number of YC companies that are helping with the crisis, and we’re looking for more startups that, if successful, could alter the trajectory of COVID-19. We’re particularly interested in startups working on: